This brings the company's total funding raised to date to $143 million.

The company is focused on the development of therapies using a new approach called intersystems biology, which leverages molecular interactions between humans, plants, and bacteria. Senda's proof-of-platform data demonstrate that its plant-derived transfer systems can deliver large biomolecules (such as mRNA and peptides) throughout the body, the company said. It is also generating preclinical data showing that its platform technology can be used to engineer bacteria-derived therapeutics that enable tunable, antigen-specific antibody and T-cell responses.

Flagship Pioneering, Senda's founder, participated in the series B financing along with new investors, including Longevity Vision Fund, Terra Magnum Capital Partners, Mayo Clinic, Partners Investment, and Mint Venture Partners. Current investors Alexandria Venture Investments and State of Michigan Retirement System also participated.